drugset / Trial / NCT03831633
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
RandomizedParallel-groupOpen-labelSupportive care
Summary
This pragmatic trial addresses the clinical gap through the generation of evidence on the comparative effectiveness between AKYNZEO® and Standard of Care (SoC, including EMEND®) in the real-life setting
Timeline
- Start
- 2018-09-19
- Primary completion
- 2019-07-31
- Completion
- 2019-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aprepitant | Other / unclassified | 80 mg | Oral |
| Subject | Netupitant | Small molecule | 300 mg | Oral |
| Comparator | Ondansetron | Other / unclassified | 8 mg | Intravenous |
| Subject | Palonosetron | Other / unclassified | 0.5 mg | Oral |
| Comparator | Dexamethasone | Small molecule | 8 mg | — |
Indications
No indication recorded.